PURPOSE: Serum B-lymphocyte stimulator (BLyS) levels have been found to be elevated in a number of immune disease models. Therefore, we sought to establish whether BLyS levels were elevated in patients with B-cell lymphoproliferative disorders and to determine whether elevated BLyS levels correlated with clinical characteristics of the disease. PATIENTS AND METHODS: Specimens were collected from the peripheral blood of individuals diagnosed with B-cell chronic lymphocytic leukemia (B-CLL; n = 70) or from age- and sex-matched patients seen at the same institution (n = 41). Serum BLyS levels were determined by enzyme-linked immunosorbent assay, and sequencing of the BLyS promoter was performed by conventional methods and confirmed by restriction fragment length polymorphism analysis. RESULTS: We found that elevated BLyS levels were more common in patients with familial B-CLL than individuals with sporadic B-CLL or normal controls. Because of this association, we sequenced the BLyS promoter in patients with B-CLL and normal controls and identified a polymorphic site, -871 C/T. We found that the wild-type sequence was significantly underrepresented in patients with familial B-CLL (4%) compared with patients with sporadic B-CLL (30%; P = .01) or controls (24%; P = .04). Furthermore, using a luciferase reporter under control of the BLyS promoter containing either a C or a T at position -871, we found that the reporter construct containing a T at -871 had a 2.6-fold increase in activity (P = .004). CONCLUSION: Our data suggest serum BLyS levels are elevated in patients with familial B-CLL and that elevated BLyS levels correlate with the presence of a T at -871 in the BLyS promoter.
PURPOSE: Serum B-lymphocyte stimulator (BLyS) levels have been found to be elevated in a number of immune disease models. Therefore, we sought to establish whether BLyS levels were elevated in patients with B-cell lymphoproliferative disorders and to determine whether elevated BLyS levels correlated with clinical characteristics of the disease. PATIENTS AND METHODS: Specimens were collected from the peripheral blood of individuals diagnosed with B-cell chronic lymphocytic leukemia (B-CLL; n = 70) or from age- and sex-matched patients seen at the same institution (n = 41). Serum BLyS levels were determined by enzyme-linked immunosorbent assay, and sequencing of the BLyS promoter was performed by conventional methods and confirmed by restriction fragment length polymorphism analysis. RESULTS: We found that elevated BLyS levels were more common in patients with familial B-CLL than individuals with sporadic B-CLL or normal controls. Because of this association, we sequenced the BLyS promoter in patients with B-CLL and normal controls and identified a polymorphic site, -871 C/T. We found that the wild-type sequence was significantly underrepresented in patients with familial B-CLL (4%) compared with patients with sporadic B-CLL (30%; P = .01) or controls (24%; P = .04). Furthermore, using a luciferase reporter under control of the BLyS promoter containing either a C or a T at position -871, we found that the reporter construct containing a T at -871 had a 2.6-fold increase in activity (P = .004). CONCLUSION: Our data suggest serum BLyS levels are elevated in patients with familial B-CLL and that elevated BLyS levels correlate with the presence of a T at -871 in the BLyS promoter.
Authors: Stephen M Ansell; Anne J Novak; Steven Ziesmer; Tammy Price-Troska; Betsy LaPlant; Stacey R Dillon; Thomas E Witzig Journal: Am J Hematol Date: 2009-02 Impact factor: 10.047
Authors: Frank Secreto; Michelle Manske; Tammy Price-Troska; Steven Ziesmer; Lucy S Hodge; Stephen M Ansell; James R Cerhan; Anne J Novak Journal: Leuk Lymphoma Date: 2014-02-24
Authors: Sherine F Elsawa; Anne J Novak; Deanna M Grote; Steven C Ziesmer; Thomas E Witzig; Robert A Kyle; Stacey R Dillon; Brandon Harder; Jane A Gross; Stephen M Ansell Journal: Blood Date: 2005-11-22 Impact factor: 22.113
Authors: James R Cerhan; Wen Liu-Mares; Zachary S Fredericksen; Anne J Novak; Julie M Cunningham; Neil E Kay; Ahmet Dogan; Mark Liebow; Alice H Wang; Timothy G Call; Thomas M Habermann; Stephen M Ansell; Susan L Slager Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-11 Impact factor: 4.254
Authors: Joanne M Hildebrand; Zhenghua Luo; Michelle K Manske; Tammy Price-Troska; Steven C Ziesmer; Wai Lin; Bruce S Hostager; Susan L Slager; Thomas E Witzig; Stephen M Ansell; James R Cerhan; Gail A Bishop; Anne J Novak Journal: J Exp Med Date: 2010-11-01 Impact factor: 14.307